Aquaporin 5 as a Target for Prophylactic Countermeasures for Pulmonary Hyperbaric Oxygen Toxicity

Abstract

PROBLEM: Exposure to high O2 causes pulmonary oxygen toxicity (POT).MISSION RELEVANCE: The impaired pulmonary function reduces performance, and toxicity can lead to serious illness or even death. PHYSIOLOGY: Divers and submariners can experience a high alveolar O2partial pressure (PAO2), leading to exaggerated O2 uptake from alveolar air into alveolar type I cells (ATICs) and then into pulmonary capillary endothelial cells (PCECs). In both cell types, a high intracellular O2 concentration ([O2]i) leads to oxidative damage. Understanding the pathophysiology and developing prophylactic countermeasures has been a high priority for Undersea Medicine. SOLUTION: Leverage newly discovered and characterized gas-channel physiology to identify new targets for adjuvant therapies. Aquaporin 5 (AQP5) is highly expressed in the apical (air-facing) membrane of ATICs. AQP5 has the highest-known CO2 permeability and is likely to conduct O2 as well. AQP1 is highly expressed in PCECs and conducts CO2 and O2.HYPOTHESIS: AQP5 mediates a substantial fraction ofO2 uptake into ATICs, and AQP1 does the same for PCECs. At high PAO2, the genetic deletion of AQP5 and/or AQP1 will reduce oxidative damage to ATICs and/or PCECs while maintaining sufficient O2 uptake for exercise. The genetic deletions, by lowing arterial PO2, may also protect the brain and other organs. LONG-TERM GOALS: This pilot project is part of a long-term plan to mitigate acute pulmonary (and perhaps CNS) oxygen toxicity in divers and submariners through development of drugs, identification of biomarkers, or extension of dive tables. Oxygen concentration is a limiting factor in Navy diving operations and disabled-submarine scenarios. APPROACH: In a model of normobaric O2 toxicity, we will determine if AQP5-knockout (KO), AQP1-KO, or double-knockout (dKO) mice experience less oxygen toxicity#based on markers of ATIC and PCEC integrity or inflammation#than their wild-type (WT) counterparts. SIGNIFICANCE: The proposed work would establish a genetic proof of principle that a reduction in AQP5 and/or AQP1 activity would be an effective countermeasure POT, and pave the way to the development of AQP inhibitors for testing in swine and humans.

Document Details

Document Type
DoD Grant Award
Publication Date
Jul 24, 2023
Source ID
N000142312555

Entities

People

  • Walter Boron

Organizations

  • Case Western Reserve University
  • Office of Naval Research
  • United States Navy

Tags

Readers

  • Cardiovascular Physiology
  • Circadian Sleep-Wake Regulation and Chronobiology
  • Immunology and Pathology

Technology Areas

  • Biotechnology